The association between sclerostin and incident type 2 diabetes risk: a cohort study

To determine whether sclerostin is associated with fasting glucose, insulin levels, insulin resistance or increased risk of incident type 2 diabetes.

[1]  Jacques P. Brown,et al.  Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. , 2016, Nutrition research.

[2]  S. Papapoulos,et al.  Sclerostin Inhibition in the Management of Osteoporosis , 2016, Calcified Tissue International.

[3]  M. Rubin,et al.  Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions , 2016, Bone Research.

[4]  S. Majumdar,et al.  Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study , 2016, The Journal of clinical endocrinology and metabolism.

[5]  P. Vestergaard,et al.  Bone Structure and Predictors of Fracture in Type 1 and Type 2 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.

[6]  Ryan T. Muir,et al.  Validity of Self-Report of Cardiovascular Risk Factors in a Population at High Risk for Stroke. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[7]  C. Jenkinson,et al.  Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism , 2015, Diabetes Care.

[8]  M. Harris,et al.  Validating self-report of diabetes use by participants in the 45 and up study: a record linkage study , 2013, BMC Health Services Research.

[9]  R. Malekzadeh,et al.  LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans. , 2013, Cell metabolism.

[10]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[11]  S. Cremers,et al.  Circulating osteogenic precursor cells in type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  R. Nuti,et al.  Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  J. A. Garcia-Salcedo,et al.  Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  Jayaram Radhakrishnan,et al.  LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors , 2007, Science.

[15]  John A Latham,et al.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.

[16]  Pamela J Schreiner,et al.  Older women with diabetes have a higher risk of falls: a prospective study. , 2002, Diabetes care.

[17]  L. Hofbauer,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[18]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[19]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[20]  S. Cummings,et al.  Older women with diabetes have an increased risk of fracture: a prospective study. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  Jacques P. Brown,et al.  Research Notes: The Canadian Multicentre Osteoporosis Study (CaMos): Background, Rationale, Methods , 1999, Canadian Journal on Aging / La Revue canadienne du vieillissement.